Table 3.
6-wk base study
|
6-mo extension study
|
|||
---|---|---|---|---|
Placebo | Etoricoxib 90 mg | Rofecoxib 25 mg | Etoricoxib 90 mg | |
Joint bleeding episodes, no. of patients (%) | 37 (72.6) | 34 (66.7) | 15 (78.9) | 57 (77.0) |
Factor use for joint bleeding episodes, no. of patients (%) | 35 (68.6) | 33 (64.7) | 15 (78.9) | 56 (75.7) |